ADVM
$10.91
Adverum Biotechnlgs
($.31)
(2.76%)
ADVM
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.35)
Revenue:  $0.46 Mil
Thursday
Nov 12
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ADVM reports earnings?
Beat
Meet
Miss

Where is ADVM's stock price going from here?
Up
Flat
Down
Stock chart of ADVM
Analysts
Summary of analysts' recommendations for ADVM
Score
Grade
Pivots
Resistance
$12.25
$11.98
$11.60

$11.32

Support
$10.94
$10.66
$10.28
Tweet
Growth
Description
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum?s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.